B. Metzler seel. Sohn & Co. AG Grows Stake in AbbVie Inc. $ABBV

B. Metzler seel. Sohn & Co. AG grew its holdings in AbbVie Inc. (NYSE:ABBV) by 5.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 498,622 shares of the company’s stock after acquiring an additional 27,906 shares during the period. AbbVie accounts for 1.0% of B. Metzler seel. Sohn & Co. AG’s portfolio, making the stock its 23rd largest holding. B. Metzler seel. Sohn & Co. AG’s holdings in AbbVie were worth $115,450,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Evolution Wealth Management Inc. purchased a new stake in AbbVie in the 2nd quarter worth $26,000. Caitlin John LLC bought a new position in shares of AbbVie during the 3rd quarter valued at approximately $33,000. Redmont Wealth Advisors LLC purchased a new position in shares of AbbVie in the 3rd quarter worth $41,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the second quarter worth about $36,000. Finally, Delos Wealth Advisors LLC bought a new position in shares of AbbVie during the 2nd quarter valued at approximately $39,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 0.8%

ABBV opened at $230.41 on Friday. The firm’s 50-day moving average price is $224.72 and its 200 day moving average price is $224.10. The firm has a market capitalization of $407.40 billion, a PE ratio of 97.63, a PEG ratio of 0.80 and a beta of 0.34. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same period last year, the business earned $2.16 earnings per share. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is currently 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY/Q1 outlook — AbbVie posted better‑than‑expected Q4 EPS and revenue and gave FY‑2026 guidance (14.37–14.57 EPS), supporting the bull case for continued top‑line and EPS growth. AbbVie (ABBV): Buy, sell, or hold post Q4 earnings?
• Positive Sentiment: Pipeline catalysts: neuroscience momentum and new approvals could drive revenue — the neuroscience unit generated ~$10.8B in 2025 and analysts see upside to ~$12.5B in 2026 as Vyalev ramps and tavapadon awaits FDA review. Will AbbVie’s Neuroscience Segment Continue to Aid Top Line in 2026?
• Positive Sentiment: Positive Phase‑3 SKYRIZI Crohn’s data strengthens the immunology franchise and expands commercial potential for risankizumab. This data is a material upside to long‑term revenue expectations for immunology products. Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
• Neutral Sentiment: Analyst/market attention: some bullish writeups call ABBV a core, buy‑and‑hold dividend name and note the stock has rallied since earnings — supportive for sentiment but already reflected in recent gains. AbbVie: The only big pharma stock I’d consider a buy-and-never-sell
• Neutral Sentiment: Operational investment: AbbVie will spend $380M to expand its North Chicago campus — a long‑term capacity/R&D bet that supports future growth but increases near‑term capex. AbbVie to invest $380 million in North Chicago campus to make next generation medicines
• Negative Sentiment: Debt issuance: AbbVie completed an $8B senior notes offering, which increases leverage and raises capital‑structure risk that investors may price in, especially given the company’s already elevated payout metrics. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Negative Sentiment: Dividend and leverage concerns: analysts caution that a very high payout ratio and significant debt levels warrant caution for income investors despite strong free cash flow. That raises risk of multiple compression if growth slows. Dividend Stock Analysis – Abbvie Inc.
• Negative Sentiment: Near‑term price pressure: recent sessions show ABBV underperforming the wider market on profit‑taking and macro moves, which can amplify volatility after the post‑earnings run. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ABBV. Piper Sandler increased their price target on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Berenberg Bank set a $275.00 price target on shares of AbbVie in a report on Tuesday, January 20th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Finally, Evercore cut their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $253.15.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.